Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Pemetrexed (Alimta) in Children With Recurrent Malignancies
2017-000095-28Phase 2
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in osteosarcoma (OS), Ewing sarcoma, medulloblastoma and 5 more, sponsored by Eli Lilly and Company. Primary endpoint: Overall tumor response rate.
02
Drugs
pemetrexed
03
Conditions
osteosarcoma (OS)Ewing sarcomamedulloblastomaneuroblastomarhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on 2017-000095-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000095-28.